Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Shares Shorted: Short Interest Down 85.9% in October

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) was the recipient of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 2,442 shares, a decrease of 85.9% from the October 15th total of 17,259 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 35,837 shares, the short-interest ratio is currently 0.1 days.

Frazier Life Sciences Acquisition Corp. II Stock Up 0.4%

Shares of NASDAQ:FLSC traded up $0.04 during trading on Wednesday, hitting $10.19. 24,700 shares of the company traded hands, compared to its average volume of 94,008. Frazier Life Sciences Acquisition Corp. II has a one year low of $10.08 and a one year high of $10.63.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a research note on Saturday, October 24th.

Insider Transactions at Frazier Life Sciences Acquisition Corp. II

In related news, CEO Albert Cha acquired 300,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was bought at an average cost of $10.00 per share, with a total value of $3,000,000.00. Following the acquisition, the chief executive officer directly owned 300,000 shares in the company, valued at approximately $3,000,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Frazier Life Sciences Acquisition Corp. II Company Profile

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to pursue a merger, asset acquisition, stock purchase, reorganization or similar business combination. Its stated focus is on businesses in the life sciences sector. As a SPAC, the company does not itself develop or sell medicines, medical devices or other products. Its role is to identify and combine with a target business, which would then operate as a public company. The company is associated with Frazier Life Sciences, the life sciences investment arm of Frazier Healthcare Partners.